Chris McNees, M.Sc.

@article{pmid29194441,

title = {Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis},

author = {Diego C P Rossi and Julie E Gleason and Hiram Sanchez and Sabrina S Schatzman and Edward M Culbertson and Chad J Johnson and Christopher A McNees and Carolina Coelho and Jeniel E Nett and David R Andes and Brendan P Cormack and Valeria C Culotta},

url = {https://pubmed.ncbi.nlm.nih.gov/29194441/},

doi = {10.1371/journal.ppat.1006763},

issn = {1553-7374},

year  = {2017},

date = {2017-12-01},

urldate = {2017-12-01},

journal = {PLoS Pathog},

volume = {13},

number = {12},

pages = {e1006763},

abstract = {Until recently, NADPH oxidase (NOX) enzymes were thought to be a property of multicellularity, where the reactive oxygen species (ROS) produced by NOX acts in signaling processes or in attacking invading microbes through oxidative damage. We demonstrate here that the unicellular yeast and opportunistic fungal pathogen Candida albicans is capable of a ROS burst using a member of the NOX enzyme family, which we identify as Fre8. C. albicans can exist in either a unicellular yeast-like budding form or as filamentous multicellular hyphae or pseudohyphae, and the ROS burst of Fre8 begins as cells transition to the hyphal state. Fre8 is induced during hyphal morphogenesis and specifically produces ROS at the growing tip of the polarized cell. The superoxide dismutase Sod5 is co-induced with Fre8 and our findings are consistent with a model in which extracellular Sod5 acts as partner for Fre8, converting Fre8-derived superoxide to the diffusible H2O2 molecule. Mutants of fre8Δ/Δ exhibit a morphogenesis defect in vitro and are specifically impaired in development or maintenance of elongated hyphae, a defect that is rescued by exogenous sources of H2O2. A fre8Δ/Δ deficiency in hyphal development was similarly observed in vivo during C. albicans invasion of the kidney in a mouse model for disseminated candidiasis. Moreover C. albicans fre8Δ/Δ mutants showed defects in a rat catheter model for biofilms. Together these studies demonstrate that like multicellular organisms, C. albicans expresses NOX to produce ROS and this ROS helps drive fungal morphogenesis in the animal host.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid25307998,

title = {Bioavailability of capsaicin and its implications for drug delivery},

author = {William D Rollyson and Cody A Stover and Kathleen C Brown and Haley E Perry and Cathryn D Stevenson and Christopher A McNees and John G Ball and Monica A Valentovic and Piyali Dasgupta},

url = {https://pubmed.ncbi.nlm.nih.gov/25307998/},

doi = {10.1016/j.jconrel.2014.09.027},

issn = {1873-4995},

year  = {2014},

date = {2014-12-01},

urldate = {2014-12-01},

journal = {J Control Release},

volume = {196},

pages = {96--105},

abstract = {The dietary compound capsaicin is responsible for the "hot and spicy" taste of chili peppers and pepper extracts. It is a valuable pharmacological agent with several therapeutic applications in controlling pain and inflammation. Emerging studies show that it displays potent anti-tumor activity in several human cancers. On a more basic research level, capsaicin has been used as a ligand to activate several types of ion-channel receptors. The pharmacological activity of capsaicin-like compounds is dependent on several factors like the dose, the route of administration and most importantly on its concentration at target tissues. The present review describes the current knowledge involving the metabolism and bioavailability of capsaicinoids in rodents and humans. Novel drug delivery strategies used to improve the bioavailability and therapeutic index of capsaicin are discussed in detail. The generation of novel capsaicin-mimetics and improved drug delivery methods will foster the hope of innovative applications of capsaicin in human disease.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid23222296,

title = {Inhibition of cholinergic signaling causes apoptosis in human bronchioalveolar carcinoma},

author = {Jamie K Lau and Kathleen C Brown and Brent A Thornhill and Clayton M Crabtree and Aaron M Dom and Theodore R Witte and W Elaine Hardman and Christopher A McNees and Cody A Stover and A Betts Carpenter and Haitao Luo and Yi C Chen and Brandon S Shiflett and Piyali Dasgupta},

url = {https://pubmed.ncbi.nlm.nih.gov/23222296/},

doi = {10.1158/0008-5472.CAN-12-3190},

issn = {1538-7445},

year  = {2013},

date = {2013-02-01},

urldate = {2013-02-01},

journal = {Cancer Res},

volume = {73},

number = {4},

pages = {1328--1339},

abstract = {Recent case-controlled clinical studies show that bronchioalveolar carcinomas (BAC) are correlated with smoking. Nicotine, the addictive component of cigarettes, accelerates cell proliferation through nicotinic acetylcholine receptors (nAChR). In this study, we show that human BACs produce acetylcholine (ACh) and contain several cholinergic factors including acetylcholinesterase (AChE), choline acetyltransferase (ChAT), choline transporter 1 (CHT1, SLC5A7), vesicular acetylcholine transporter (VAChT, SLC18A3), and nACh receptors (AChRs, CHRNAs). Nicotine increased the production of ACh in human BACs, and ACh acts as a growth factor for these cells. Nicotine-induced ACh production was mediated by α7-, α3β2-, and β3-nAChRs, ChAT and VAChT pathways. We observed that nicotine upregulated ChAT and VAChT. Therefore, we conjectured that VAChT antagonists, such as vesamicol, may suppress the growth of human BACs. Vesamicol induced potent apoptosis of human BACs in cell culture and nude mice models. Vesamicol did not have any effect on EGF or insulin-like growth factor-II-induced growth of human BACs. siRNA-mediated attenuation of VAChT reversed the apoptotic activity of vesamicol. We also observed that vesamicol inhibited Akt phosphorylation during cell death and that overexpression of constitutively active Akt reversed the apoptotic activity of vesamicol. Taken together, our results suggested that disruption of nicotine-induced cholinergic signaling by agents such as vesamicol may have applications in BAC therapy.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}